Researchers have uncovered that the infection rates of high risk human papillomavirus (HR-HPV) in England are lower than expected. Research also found that smoking and sexual behaviour were risk factors for the infection, leading to throat cancer.
The Joint Committee on Vaccination and Immunisation has stated that a gender-neutral vaccine program would be cost effective in the UK and would protect boys against HPV infection and associated diseases.
A recent study has demonstrated a significant decrease in cases of human papilloma virus infection in England since the introduction of a bivalent vaccine in 2008.
The human papillomavirus (HPV) vaccine has recently attracted considerable attention in emerging countries. In this research article, the authors carry out a multi-country case study investigating the the adoption and use of HPV vaccines.
Could one vaccine dose be as effective as two or three doses at preventing persistent HPV infection in the cervix in young women? This review discusses HPV vaccine coverage and the possibility of a one-dose schedule.